Skip to main content

Table 3 Summary of C-KIT Trials

From: Therapy for metastatic melanoma: the past, present, and future

Trial Patients RR%
(CR/PR)
PFS
(month)
OS Number
(patients)
Summary
Single Arm Phase 2
Kim KB et al. [52]
Imatinib mesylate 400 mg bid in advanced unresectable melanoma 5% 1.4 7.5 months 21 Imatinib mesylate demonstrated a response in 1 patient who also had high c-kit expression and alternate splicing variant in c-kit mRNA transcript.
Single Arm Phase 2
Carvajal et al. [54]
Imatinib mesylate 400 mg bid in advanced unresectable melanoma 16% 3 46.3
weeks
28 Imatinib mesylate demonstrated a significant clinical response in subset of patients with cKit mutation and advanced melanomaa
Single Arm Phase 2
Guo et al. [53]
Imatinib mesylate 400 mg daily in metastatic melanoma 23.3% 3.5 14
months
43 Imatinib mesylate demonstrated a significant clinical response in a subset of patients with cKit mutation and metastatic melanomaa
  1. athe clustering of responses in both trials were seen in patients harboring c-kit mutations at exon 11 or exon 13; c-kit overexpression on IHC without a mutation did not correlate with a response. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.